Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Financials
52W LOW $24.0152W HIGH $44.56
Volume
7.56 M
Value Traded
333.68 M
Short % Float
2.5%
Days to Cover
5.3
+3.56%Week
+8.25%1 Month
+22.05%3 Month
+30.77%6 Month
+215.46%5 Year
+5,163.2%All Time
Cash Data
- Cash FlowProfitable
- SEC Filing
Key Stats
Market Cap
51.92 B
EPS (TTM)
0.43
P/E Ratio
102.42
Ent. Value
51.88 B
Total Shares
1.17 B
Float Shares
1.11 B
Insiders
4.90%
Institutions
50.48%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
TEVA Catalyst Timeline
Dated clinical, regulatory and corporate events for Teva Pharmaceutical Industries Limited
Catalyst Timeline
Dated clinical, regulatory & corporate events for Teva Pharmaceutical Industries Limited
172Total events
16Upcoming
61Tier-1 (high impact)
2016 to 2030Coverage
Upcoming catalysts 2
Event history 50
●R&D DayPresentation
Teva hosts first-ever R&D Day outlining pipeline and 2030 growth targets
▲Partnership / LicenseETICOVOCorporate
Teva and Samsung Bioepis enter U.S. license and commercialization agreement for ETICOVO (etanercept-ykro) and infliximab-abda
chronic inflammatory and autoimmune conditionssource ↗
▼Trial Stopped FutilityemrusolminTrial
Teva to discontinue Phase 2 TOPAS-MSA study of emrusolmin in MSA following interim futility analysis
multiple system atrophy (MSA)source ↗
▼DSMB ReviewemrusolminTrial
Independent data monitoring committee recommended discontinuation of TOPAS-MSA
multiple system atrophy (MSA)source ↗
▼Interim AnalysisemrusolminTrial
Interim futility analysis of TOPAS-MSA met predefined futility criterion
multiple system atrophy (MSA)source ↗
▲AcquiredBXCL-501FiledCorporate
Teva completes acquisition of BioXcel neuroscience assets including worldwide rights to BXCL501
acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adultssource ↗
▲FDA ApprovalWELTRUZA™ApprovedFDA Decision
FDA approves WELTRUZA (olanzapine) extended-release injectable suspension for schizophrenia in adults
schizophreniasource ↗
●Oral PresentationecopipamFiledPresentation
New ecopipam efficacy and safety data presented at MDS Congress in Seoul
pediatric patients with Tourette syndromesource ↗
▲Subgroup AnalysisecopipamFiledClinical Data
Post hoc analysis: co-occurring psychiatric conditions did not impact ecopipam efficacy or safety
Tourette syndrome with co-occurring psychiatric conditionssource ↗
▲Interim AnalysisecopipamFiledTrial
Interim 18-month OLE analysis: 45.6% mean reduction in tic severity, no new safety signals
Tourette syndromesource ↗
▲Topline ReadoutecopipamFiledClinical Data
Post hoc pooled analysis: ~70% clinically meaningful tic reduction within 8 weeks
Tourette syndromesource ↗
●Preclinical PoCecopipamFiledPreclinical
Preclinical receptor selectivity findings for ecopipam presented at MDS
Tourette syndromesource ↗
●PublicationecopipamFiledPresentation
Journal of Child Neurology publishes review on dopamine pathways and ecopipam in Tourette syndrome
Tourette syndrome in pediatric patientssource ↗
▲Partnership / LicenseCorporate
Samsung Bioepis and Teva enter global license, development and commercialization agreement for up to six potential biosimilar candidates
▲FDA ApprovalWELTRUZA™ApprovedFDA Decision
FDA approved WELTRUZA for long-acting injectable schizophrenia treatment
schizophreniasource ↗
▲FDA ApprovalDEGEVMAApprovedFDA Decision
FDA approves DEGEVMA (denosumab-adet), a biosimilar to Xgeva
prevention of bone complications in adults with advanced cancer that has spread to the bone; giant cell tumor of bone; hypercalcemia of malignancysource ↗
▲Topline ReadoutecopipamFiledClinical Data
D1AMOND Phase 3 ecopipam trial results in Tourette syndrome
Tourette syndromesource ↗
▼Trial Stopped FutilityemrusolminTrial
Teva discontinued Phase 2 MSA study of emrusolmin (TEV-‘286) after interim futility analysis
Multiple System Atrophysource ↗
▲Topline ReadoutTEV-’408Clinical Data
Positive Phase 2a results for anti-IL-15 (TEV-‘408) in Celiac disease
Celiac diseasesource ↗
▲FDA Filing AcceptedecopipamFiledRegulatory Filing
FDA accepted ecopipam NDA for review in pediatric Tourette syndrome
Tourette syndromesource ↗
▲AcquiredBXCL-501FiledCorporate
Teva acquired BXCL-501 from BioXcel Therapeutics
agitation associated with schizophrenia or bipolar I or II disordersource ↗
▲Partnership / LicenseCorporate
Deepened collaboration with Samsung Bioepis for infliximab-abda and etanercept-ykro biosimilars
●EU MAA SubmissionTEV-‘749ApprovedEx-US Regulatory
EMA accepted MAA for olanzapine long-acting injectable (TEV-‘749) for schizophrenia
schizophreniasource ↗
▲FDA ApprovalPONLIMSIApprovedFDA Decision
FDA approved PONLIMSI (denosumab-adet) in March 2026
indications of Prolia (denosumab)source ↗
▲Full ResultsecopipamFiledClinical Data
Phase 3 ecopipam Tourette syndrome results published in JAMA Neurology
Tourette syndromesource ↗
▲EU ApprovalDEGEVMAApprovedEx-US Regulatory
DEGEVMA approved in the European Union
biosimilar to Xgeva (denosumab)source ↗
▲Fast Track DesignationemrusolminDesignation
FDA granted Fast Track designation to emrusolmin for MSA
multiple system atrophy (MSA)source ↗
▲Long Term DataecopipamFiledClinical Data
12-month open-label extension data for ecopipam in pediatric Tourette syndrome published
Tourette syndromesource ↗
▲PublicationecopipamFiledPresentation
12-month ecopipam open-label safety data published in Movement Disorders Clinical Practice
Tourette syndrome in pediatric patientssource ↗
▲Long Term DataecopipamFiledClinical Data
12-month open-label extension shows sustained tic severity reductions with ecopipam
Tourette syndrome in pediatric patientssource ↗
▲Primary Endpoint MetClinical Data
Positive Phase 3 efficacy results for olanzapine Once-Monthly LAI
schizophreniasource ↗
◆Timing GuidancePresentation
Initial program results expected in 2024
Ulcerative Colitis and Crohn's Diseasesource ↗
▲Product LaunchNarcanPost-Market
Expansion of generic Narcan shipments expected under nationwide settlement
opioid overdosesource ↗
▲Codev CocommercialCorporate
Sanofi and Teva announce exclusive collaboration to co-develop and co-commercialize TEV 574
Ulcerative Colitis and Crohn's Diseasesource ↗
Past FDA Catalysts and PDUFA Decisions
How TEVA actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-10-09 | TEV-'749 (subcutaneous olanzapine LAI; TV-44749) | PDUFA Date Approved | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Commercial Value
Valuation Signal
8
Drugs Scored
rNPV / MCap
Top Drug
Top 5%
Large Pharma(rank 35 of 689)
Percentile Rank
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Sep 2026; product lines: last four quarters to Sep 2026 (10-K and 10-Q))
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| Austedo | |||
| AJOVY | |||
| COPAXONE | |||
| UZEDY | |||
| BENDEKA and TREANDA |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| TEV-56248 Small MoleculesNCT06052267 | Asthma | Phase 3 | ACTIVE NOT_RECRUITING | 3,448 | Dec 31, 2026 | ||||||
| TEV-56278 Small MoleculesNCT06480552 | Advanced Solid Tumors | Phase 1 | RECRUITING | 240 | Feb 25, 2031 | ||||||
| TEV-53408 Small MoleculesNCT07920211 | Vitiligo | Phase 2/3 | NOT YET_RECRUITING | 1,086 | Jun 19, 2031 | ||||||
| TEV-53408 Small MoleculesNCT06807463 | Celiac Disease | Phase 2 | ACTIVE NOT_RECRUITING | 50 | Sep 14, 2027 | ||||||
| TEV-56286 Small MoleculesNCT06568237 | Multiple System Atrophy | Phase 2 | ACTIVE NOT_RECRUITING | 549 | Sep 15, 2027 | ||||||
| AKLIEF Small MoleculesCompletedNCT05550337 | Acne Vulgaris | Phase 3 | COMPLETED | 807 | May 9, 2023 | ||||||
| TEV-48574 Small MoleculesCompletedNCT05499130 | Crohn Disease | Phase 2 | COMPLETED | 290 | Nov 12, 2024 | ||||||
| TV-46046 Small MoleculesCompletedNCT04682353 | Contraception | Phase 1 | COMPLETED | 87 | Jan 12, 2023 | ||||||
| anle138b Small MoleculesCompletedNCT05532358 | Undisclosed | Phase 1 | COMPLETED | 54 | Feb 10, 2023 | ||||||
| Reslizumab BiologicsMarketedNCT01285323 | Eosinophilic Asthma | Approved | COMPLETED | 1,779 | Apr 1, 2014 | ||||||
| Reslizumab BiologicsMarketedNCT02559791 | Severe Persistent Asthma | Approved | COMPLETED | 10 | Aug 1, 2017 | ||||||
| Reslizumab BiologicsMarketedNCT00587288 | Asthma | Approved | COMPLETED | 751 | Mar 1, 2010 | ||||||
| TEV-45779 Small MoleculesCompletedNCT04976192 | Chronic Urticaria | Phase 3 | COMPLETED | 608 | Apr 5, 2024 | ||||||
| BDP HFA Small MoleculesMarketedNCT01307319 | Seasonal Allergic Rhinitis | Approved | COMPLETED | 715 | Aug 1, 2011 | ||||||
| albuterol by HFA MDI Small MoleculesMarketedNCT00085774 | Exercise-induced Bronchospasm | Approved | COMPLETED | 24 | Sep 30, 2004 | ||||||
| Fluticasone Propionate/Salmeterol MDPI Small MoleculesMarketedNCT02980133 | Asthma | Approved | COMPLETED | 1,840 | Apr 13, 2019 | ||||||
| BDP Small MoleculesMarketedNCT01697956 | Allergic Rhinitis | Approved | COMPLETED | 646 | Feb 1, 2013 | ||||||
| Beclomethasone dipropionate Small MoleculesMarketedNCT01024608 | Seasonal Allergic Rhinitis | Approved | COMPLETED | 340 | Feb 28, 2010 | ||||||
| Beclomethasone dipropionate Small MoleculesMarketedNCT00109668 | Asthma | Approved | COMPLETED | 1,968 | Sep 30, 2006 | ||||||
| Armodafinil Small MoleculesNot countedNCT00078325 | Obstructive Sleep Apnea | Phase 3 | COMPLETED | 658 | Nov 1, 2004 | ||||||
| Beclomethasone dipropionate Small MoleculesMarketedNCT00988247 | Perennial Allergic Rhinitis | Approved | COMPLETED | 636 | Feb 28, 2011 | ||||||
| Reslizumab BiologicsNot countedNCT00538434 | Eosinophilic Esophagitis | Phase 3 | COMPLETED | 417 | Oct 1, 2009 | ||||||
| TVB-009 Small MoleculesCompletedNCT04729621 | Osteoporosis, Postmenopausal | Phase 3 | COMPLETED | 332 | Jun 19, 2023 | ||||||
| SD-809 Small MoleculesMarketedNCT01897896 | Chorea Associated With Huntington Disease | Approved | COMPLETED | 119 | Aug 21, 2017 | ||||||
| Fremanezumab BiologicsMarketedNCT04464707 | Migraine | Approved | COMPLETED | 5,286 | Nov 29, 2024 |
Clinical Trial Results
Readouts, endpoints and source filings for every TEVA program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| ecopipam PriorityFast TrackOrphan | Tourette syndrome | Phase 3 | 2026-10-02 | continued ecopipam treatment cut the risk of tic relapse by 50% versus placebo in pediatric participants (HR: 0.5; P=0.008)Read More | Journal of Child Neurology Publishes Review Highlighting Dopamine’s Role in Tourette Syndrome and Ecopipam’s Selective D1 Receptor Mechanism for Tourette Syndrome in Pediatric PatientsRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Sabag MarkOfficer (See "Remarks") | Option | 44,710 125,470 held | $34.90 | 11/12/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in TEVA
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| TRI LOCUM PARTNERS LP | 3.1 % (-27.9 %) | 25.30 M | 746.84 K | -26.85% ( -274.17 K) |
Ownership Trends
TEVA Short Interest
Shares sold short, counted twice a month.
2.5%
Short % of Float
of tradable shares sold short
27.7M
Shares Sold Short
-1.2% vs prior count
5.3 High
Days to Cover
trading days of normal volume to buy every short share back
5.2M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How TEVA ranks across every disease it competes in
Competitive Position is a premium feature
See how TEVA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialTEVA News
TEVA▲ +2%today
Teva Shares Innovative Pipeline Updates and Unveils Path to Future Growth at R&D Day, Targeting $6–7 Billion in Innovative Medicines Revenue by 2030
Teva Pharmaceutical Industries hosted its first R&D Day, revealing plans to achieve $6-7 billion in innovative medicines revenue by 2030. The company has doubled its revenue from innovative medicines since 2023 and aims to launch one new medicine annually over the next five years. Teva's pipeline includes several promising candidates in various stages of development.
Read more →TEVATeva’s Pivot to Growth Strategy Delivers 33% Growth Across Key Innovative Brands; Raises 2026 Outlook for AUSTEDO®, AJOVY® and UZEDY®; Delivers Substantial Gross Margin Expansion
Teva Pharmaceutical Industries reported Q3 2026 revenues of $4.4 billion, a 2% decrease year-over-year, primarily due to lower generics sales. However, key innovative brands grew by 33%, prompting the company to raise its revenue outlook for 2026. The FDA approved WELTRUZA, enhancing Teva's schizophrenia treatment portfolio, while the acquisition of BXCL-501 expands its pipeline.
Read more →TEVATeva and Samsung Bioepis Announce Agreement to Commercialize Two FDA-Approved Biosimilars in the U.S.
Teva Pharmaceutical and Samsung Bioepis have entered a commercialization agreement for two FDA-approved biosimilars: infliximab-abda and ETICOVO. Teva will gain U.S. rights for ETICOVO immediately and for infliximab-abda in Q3 2027. This collaboration aims to enhance Teva's immunology portfolio and expand patient access to biologic treatments.
Read more →TEVATeva to Discontinue Phase 2 TOPAS-MSA Study of emrusolmin (TEV-‘286) Following Interim Futility Analysis
Teva Pharmaceuticals announced the discontinuation of the Phase 2 TOPAS-MSA study for emrusolmin after an interim futility analysis indicated a low likelihood of meeting its primary efficacy endpoint. No safety concerns were noted, and a comprehensive evaluation of available data will follow. The decision does not affect the broader emrusolmin program.
Read more →TEVATeva Acquires Worldwide Rights to BXCL501, Further Expanding Innovative Neuroscience Pipeline
Teva Pharmaceuticals has acquired worldwide rights to BXCL501, a dexmedetomidine sublingual film, from BioXcel Therapeutics. This investigational treatment is under FDA review for at-home use in managing agitation associated with schizophrenia or bipolar disorders. The acquisition aligns with Teva's strategy to enhance its neuroscience portfolio and address significant patient needs.
Read more →TEVATeva to Host R&D Day on Wednesday, November 11 in New York City
Teva Pharmaceutical Industries Ltd. will host an R&D Day on November 11, 2026, in New York City. The event aims to showcase Teva's R&D pipeline and discuss its transformation strategy aimed at growth. Presentations will be available via live webcast, but in-person attendance is limited to invited guests only.
Read more →TEVATeva Announces U.S. Food and Drug Administration (FDA) Approval of WELTRUZA™ (Olanzapine) For Extended-Release Injectable Suspension, as the First and Only Once-Monthly Subcutaneous Injectable Olanzapine for Adults with Schizophrenia
Teva Pharmaceuticals has received FDA approval for WELTRUZA (olanzapine), a once-monthly subcutaneous injectable for treating schizophrenia in adults. This innovative formulation requires no loading doses or oral supplementation and has shown significant symptom improvement in clinical trials. WELTRUZA aims to enhance adherence and reduce relapse rates among patients. It will be available in three strengths soon.
Read more →TEVATeva Presents New Efficacy and Safety Data with Ecopipam, an Investigational Treatment for Pediatric Patients with Tourette Syndrome
Teva Pharmaceuticals presented new efficacy and safety data for ecopipam, an investigational treatment for pediatric Tourette syndrome, at the International Congress of Parkinson’s Disease and Movement Disorders. The data revealed that approximately 70% of participants experienced clinically meaningful tic reduction within 8 weeks. An interim analysis also indicated a sustained reduction in tic severity over 18 months without new safety concerns.
Read more →TEVAJournal of Child Neurology Publishes Review Highlighting Dopamine’s Role in Tourette Syndrome and Ecopipam’s Selective D1 Receptor Mechanism for Tourette Syndrome in Pediatric Patients
Teva Pharmaceuticals announced a review published in the Journal of Child Neurology, discussing dopamine's role in Tourette syndrome and the potential of ecopipam, a selective D1 receptor antagonist. The review suggests that ecopipam may effectively reduce tic severity in pediatric patients while avoiding common side effects associated with traditional antipsychotics. Clinical trial data supports its efficacy and tolerability, highlighting its innovative approach to treatment.
Read more →TEVASamsung Bioepis and Teva Expand Strategic Partnership to Advance Up to Six Potential Biosimilar Candidates
Samsung Bioepis and Teva have expanded their strategic partnership to include the development of up to six potential biosimilar candidates. The agreement specifically mentions SB41 and SB44, referencing Fasenra and Ilaris, respectively. This collaboration aims to leverage Samsung's development and manufacturing strengths alongside Teva's global commercialization capabilities, enhancing access to biosimilars in key markets.
Read more →TEVATAPI (Technology & API Services) Names Serge Rogasik CEO to lead next chapter of growth and competitiveness
TAPI has appointed Serge Rogasik as its new CEO to lead the company into its next growth phase. Rogasik, with over 25 years of experience, aims to leverage TAPI's extensive capabilities in active pharmaceutical ingredients and contract development and manufacturing. The company is positioned to support the pharmaceutical industry's focus on supply chain resilience and geographic diversification. TAPI will showcase its offerings at CPHI Milan in October 2026.
Read more →TEVATeva Continues Biosimilar Momentum with U.S. FDA Approval of DEGEVMA™ (denosumab-adet), a Biosimilar to Xgeva® (denosumab)
Teva Pharmaceutical Industries has received FDA approval for DEGEVMA™ (denosumab-adet), a biosimilar to Xgeva® (denosumab). This approval covers all indications of the reference product, including preventing bone complications in advanced cancer patients. DEGEVMA is Teva's second FDA-approved biosimilar in 2026, enhancing its denosumab portfolio and supporting its growth strategy.
Read more →TEVATeva Releases Q3 2026 Aide Memoire
Teva Pharmaceutical Industries Ltd. announced the availability of its Q3 2026 Aide Memoire, which compiles public information to assist investors ahead of the upcoming quarterly results. The results are expected to be released on November 3, 2026, followed by a conference call. The document outlines management's previous commentary and includes forward-looking statements that highlight potential risks.
Read more →TEVATeva to Host Conference Call to Discuss Third Quarter 2026 Financial Results on November 3, 2026 at 8 a.m. ET
Teva Pharmaceutical Industries Ltd. will release its third quarter 2026 financial results on November 3, 2026, at 7:00 a.m. ET. A conference call and live webcast will follow at 8:00 a.m. ET. Participants must register in advance to join the call. A replay will be available on Teva's website within 24 hours post-call.
Read more →TEVANew Teva Study Identifies the Attributes that Healthcare Providers Prioritize when Selecting a Treatment for Tardive Dyskinesia in Older Patients
Teva Pharmaceuticals presented new data at Psych Congress detailing healthcare providers' preferences for treating tardive dyskinesia (TD) in older patients. Key attributes influencing treatment decisions include drowsiness risk and long-term efficacy. AUSTEDO emerged as the preferred VMAT2 inhibitor, aligning with provider priorities. The findings underscore the need for effective TD management.
Read more →TEVATeva Highlights New Real-World Data Showing UZEDY® (risperidone) Outperforms Other Long-Acting Injectables in Keeping Schizophrenia Patients on Treatment, While Reducing Emergency Care and Healthcare Costs
Teva Pharmaceuticals announced new real-world data demonstrating that UZEDY (risperidone) significantly outperforms other long-acting injectables for schizophrenia and bipolar I disorder. The findings indicate that UZEDY enhances treatment adherence, reduces emergency care visits, and lowers healthcare costs, with an average savings of over $1,000 per patient per month. These results were presented at Psych Congress 2026.
Read more →TEVATeva Announces New Olanzapine LAI (TEV-'749) Post Hoc Data Highlighting High Rates of Stabilization and Long-Term Efficacy as Once-Monthly Subcutaneous Injectable for the Treatment of Schizophrenia in Adults
Teva Pharmaceuticals presented new post hoc data on TEV-'749, a once-monthly injectable formulation of olanzapine for schizophrenia, highlighting its efficacy and safety from the Phase 3 SOLARIS trial. Over half of participants achieved stabilization, with low relapse rates. The findings support the potential of TEV-'749 as a treatment option for patients switching from daily oral olanzapine.
Read more →TEVATeva Launches LongActingImpact.com to Advance Understanding of Earlier, Effective and Uninterrupted Schizophrenia Care
Teva Pharmaceuticals has launched LongActingImpact.com, a new educational resource aimed at healthcare providers to facilitate informed discussions about long-acting injectables (LAIs) for schizophrenia care. The site offers guidance on the benefits of LAIs, strategies for improving medication adherence, and support for continuity of care. This initiative addresses the challenges of treatment adherence, which affects a significant portion of patients with schizophrenia.
Read more →TEVATeva Begins Trading Ordinary Shares Directly on the NYSE, Marking a Milestone in its Pivot to Growth Strategy
Teva Pharmaceutical Industries Ltd. has commenced trading its ordinary shares directly on the NYSE, marking a significant step in its Pivot to Growth strategy. This transition is expected to enhance investor access and reflects the company's financial strength, bolstered by recent investment-grade ratings. Teva aims to leverage its innovative medicines portfolio to drive sustainable growth and shareholder value.
Read more →TEVATeva Announces Successful Pricing of $4.9 billion (Equivalent) Senior Notes
Teva Pharmaceutical Industries Ltd. has successfully priced approximately $4.9 billion in senior notes. The proceeds will be utilized for conditional redemptions of existing notes and general corporate purposes. The settlement is anticipated around September 16, 2026, subject to customary closing conditions. Teva's financial strategy aims to enhance its capital structure while managing existing debt.
Read more →About Teva Pharmaceutical Industries Limited
HeadquartersTEVA PHARMACEUTICAL INDUSTRIES LIMITED, TEL AVIV
BIOPHARMAWATCH ELITE
Trade the next TEVA catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime